Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis

por Merlini, G, Lousada, I, Ando, Y, Dispenzieri, A, Gertz, M A, Grogan, M, Maurer, M S, Sanchorawala, V, Wechalekar, A, Palladini, G, Comenzo, R L
Publicado 2016

P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE

por Vaxman, I., Kumar, S., buadi, F., Lacy, M., Dingli, D., Fonder, A., Hobbs, M., Hayman, S., hwa, L. Y., Kouralis, T., Warsame, R., Muchtar, E., Nelson, L., Kapoor, P., Grogan, M., Go, R., Gonsalves, W., Siddiqi, M., Robert, K., Rajkumar, V., Gertz, M., Dispenzieri, A.
Publicado 2022

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

por Vaxman, I., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hwa, Y., Fonder, A., Hobbs, M., Hayman, S., Kourelis, T., Warsame, R., Muchtar, E., Leung, N., Kapoor, P., Grogan, M., Go, R., Lin, Y., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Gertz, M. A., Dispenzieri, A.
Publicado 2021